Stanford Health Care’s Janjri Desai, Pharm.D., says pharmacists improve outcomes but often can’t bill for it, making billing parity key to growing services.
|Slideshows|July 30, 2020
- MHE July 2020
- Volume 30
- Issue 7
MHE 2020 Annual Pharmacy Survey pt. 2
Author(s)MHE Staff
Listen
0:00 / 0:00
As it has done with so much else in healthcare, COVID-19 dominated our 2020 annual pharmacy survey. The disease was addressed in 10 of our 13 areas we covered, either within the question itself or as a possible answer. Second of three parts. See more in our Surveys tab.
Advertisement
Overall, the responses paint a picture of the pandemic having a major impact, which is not surprising, and reveal some optimism; for example, 78% of the respondents expect to see at least limited use of a COVID-19 vaccine by the first quarter of 2021.
Articles in this issue
over 6 years ago
Upping the Cardiovascular Health Gameover 6 years ago
MHE 2020 Annual Pharmacy Survey pt. 3over 6 years ago
New Drugs Take Aim at Autoimmune Diseasesover 6 years ago
Is the Biosimilars Waiting Game Finally Over?over 6 years ago
Racial Disparities in Cancer Enter the Spotlightover 6 years ago
MHE 2020 Annual Pharmacy Surveyover 6 years ago
Opinion: The Future of Pharmacy Care Services, Post-Pandemicover 6 years ago
Has the C-Suite Gotten Too Big?over 6 years ago
Protecting the Integrity of EHR Clinical Decision Support ToolsAdvertisement
Related to this article
Stanford Health Care’s Janjri Desai, Pharm.D., says pharmacy should be treated as a clinical service line, not just a 340B financial workhorse.
Speakers and researchers at this year's meeting in San Diego focused on drug pricing policy, getting savings to patients at the pharmacy counter and keeping people in charge of AI.
The generic twice-yearly HIV prevention shot is expected to cost $40 a year in 120 countries, 16 months after Gilead's original approval.
Annual healthcare costs jump by almost $25,000 with targeted therapy for atopic dermatitis that avoided costs from reduced hospitalizations and ER visits only partly offset, according to recently reported research findings.
Findings from an analysis of IQVIA claims data show a prevalence rate that is five times lower than previous reports. Some of the discrepancy could be chalked up to the difference between using claims data instead of self-reporting by survey respondents.
In the MDT-BRIDGE trial, 92% of patients with stage II-III lung cancer reached surgery or chemoradiation after a midtreatment tumor board review.
Epic Research finds over half of children with type 1 diabetes miss autoantibody testing, risking misdiagnosis and limiting early treatment options like Tzield.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FDA tentatively approves first generic lenacapavir for HIV prevention in lower-income countries
2
New pulmonary fibrosis drugs put guidelines in focus, Prusi says | AMCP Nexus 2026
3
Fewer than half of newly diagnosed children with type 1 diabetes get autoantibody testing
4
Targeted therapies for atopic dermatitis reduce hospitalizations and ER visits, but cost is a different story
5